Tata Chemicals Ltd. is in advanced talks to acquire the industrial salt unit of Archean Group that could value the business at 4.5 billion rupees ($61 million) at a minimum, according to people familiar with the matter. The board of Tata Chemicals is set to discuss the potential offer as soon as this month, said the people, who asked not to be identified as the information is private. Negotiations are ongoing and could still fall apart, the people said. A representative for Archean declined to comment, while a representative for Tata Chemicals didn’t provide any immediate comment. A potential deal could offer a reprieve to Archean, which has been struggling to service its debt obligations for the past two years. The Chennai-based company, founded in 1982, has businesses spanning from industrial salt, fertilizers to mining, according to its website.
Subscribe
Nomad Foods eyes ‘beachhead’ in central and eastern Europe with ‘exclusive negotiations’ to acquire Fortenova’s frozen business By Katy Askew Frozen food specialist Nomad Foods has entered into ‘exclusive negotiations’ to acquire the frozen food business of Croatia’s Fortenova Group. The move demonstrates Nomad’s ambition to expand in what it describes as ‘developing’ European markets and deliver its dual-pronged strategy to grow organically and through M&A.
As CEO Stéfan Descheemaeker explained after the company’s most recent quarterly update, the coronavirus pandemic has acted as a ‘tailwind’ for companies like Nomad, who offer convenience and a long shelf life. And an aggressive rollout of Green Cuisine plant-based items across Europe is also helping to lift revenue.
Press release content from Globe Newswire. The AP news staff was not involved in its creation.
DIACCURATE acquires BIOKINESIS to create a sole-in-class biotech player in oncology and .
DIACCURATEJanuary 12, 2021 GMT
Dr. Dominique BRIDON leads the new entity
DIACCURATE is now developing 3 programs in cancer and immunotherapy
DIACCURATE will be initiating a first clinical trial by early 2022
Paris, France, January 12, 2021
By acquiring BIOKINESIS, a French biotech that develops the very first anticancer compound targeting the Golgi apparatus, DIACCURATE comforts its “sole-in-class” therapeutic strategy in oncology and immunotherapy. The company is developing a new generation of drug candidates which relies on novel mechanisms of action and untapped cellular and subcellular compartments. Initial data already suggest that this highly innovative approach could help to improve resitance to cancer progression and extend the benefits of immunotherapy to more indications and pati
Press release content from Business Wire. The AP news staff was not involved in its creation.
CI Financial’s Total Assets Grow 27% in 2020 to Record $231.5 Billion
January 12, 2021 GMT
TORONTO (BUSINESS WIRE) Jan 12, 2021
CI Financial Corp. (“CI”) (TSX: CIX, NYSE: CIXX) today reported preliminary assets under management as at December 31, 2020 of $134.9 billion and wealth management assets of $96.6 billion, for total assets of $231.5 billion.
ADVERTISEMENT
CI’s wealth management assets and total assets grew by 91.3% and 27.1% year over year, respectively, reaching record highs.
“In December, we completed the acquisition of four U.S. wealth management firms, adding approximately $12.3 billion in assets and a presence in four large and vital markets,” said Kurt MacAlpine, CI Chief Executive Officer.